Skip to main content
NIH funding notice RFA-CA-23-004

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closed on September 1, 2023.

Posted
December 2, 2022
Close date
September 1, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $203,610 in first-year total cost, median $203,610.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 TCRB-J (M1)]1

Most frequent institutions

  1. UNIVERSITY OF TEXAS AT AUSTIN1
Competing awards under RFA-CA-23-004 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Precision Tumor Sampling of Melanoma Using Laser Microbiopsy1R61CA291212-01PAREKH, SAPUN HTUNNELL, JAMES WUNIVERSITY OF TEXAS AT AUSTIN, TX$203,610ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-23-004: Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | ScienceDex | ConductScience